OUR INSTITUTES: CANCER | HEART | NEUROSCIENCE | ORTHOPAEDICS
 
 

Hyundai Cancer Institute :: Clinical Trials
Share |
Printer Friendly

The Hyundai Cancer Institute at CHOC Children's, a member of the Children’s Oncology Group, provides patients with access to state-of-the-art clinical research trials. A clinical trial is a research study that aims to determine the most effective treatment for a particular disease. Each trial is a result of a very detailed study of factors associated with the most current standard treatment and variables that may lead to an improvement in survival rates or a reduction in side effects or late effects of treatment. 

Through our Childrens Oncology Group (COG) membership, the Hyundai Cancer Institute at CHOC Children's received a prestigious Phase I clinical trial designation, making us one of only 22 facilities in North America offering COG's groundbreaking alternative treatments. 

For more information on participation in clinical trials, contact the CHOC Research Institute at (714) 509-4341.

 
Search Results:
  • Category: Oncology
    IRB Code: 110876
    Study Title: 10-CBA: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)for transplantation in pediatric and adult patients with hematologic malignancies and other indications
  • Category: Oncology
    IRB Code: 120542
    Study Title: A Hyundai Cancer Institute Pilot Protocol to Determine the Incidence of Vitamin D Deficiency in Newly Diagnosed Pediatric Acute Lymphoblastic Leukemia (ALL) Patients
  • Category: Oncology
    IRB Code: 809104
    Study Title: A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx?, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects with Hematologic Malignancies following Myeloablative Therapy
  • Category: Oncology
    IRB Code: 120104
    Study Title: A multi-center, open-label, pharmacokinetic study of oral nilotinib in pediatric patients with Gleevac (imatinib)-resistant/intolerant Ph CML chronic phase (CP) or accelerated phase (AP) or with refractory/relapsed Ph ALL
  • Category: Oncology
    IRB Code: 100655
    Study Title: A Phase I Trial for Refractory or Relapsed Neuroblastoma with DFMO Alone and in Combination with Etoposide
  • Category: Oncology
    IRB Code: 1011113
    Study Title: A phase I/II, open-label, dose-escalating study to evaluate the safety, tolerability and pharmacokinetics of twice daily oral midostaurin and to evaluate the preliminary clinical and pharmacodynamic response in pediatric patients with relapsed or refractory leukemia
  • Category: Oncology
    IRB Code: 90325
    Study Title: A Phase II Study of Dasatinib Therapy in Children and Adolescents with Newly Diagnosed Chronic Phase CML or with Ph+ Leukemias Resistant or Intolerant to Imatinib
  • Category: Oncology
    IRB Code: 110670
    Study Title: A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Patients
  • Category: Oncology
    IRB Code: 90652
    Study Title: AALL0433, Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies
  • Category: Oncology
    IRB Code: 70327
    Study Title: AALL0434 Intensified Methotrexate, Nelarabine (Compound 506U78; IND# 52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Lymphoma
  • Category: Oncology
    IRB Code: 80221
    Study Title: AALL0631, A Phase III Study of Risk Directed Therapy for Infants with Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807)
  • Category: Oncology
    IRB Code: 70745
    Study Title: AALL06N1 A Study of Neurocognitive Function in Children Treated for ALL.
  • Category: Oncology
    IRB Code: 90324
    Study Title: AALL07P1 A Phase II Pilot Trial of Bortezomib (PS-341, Velcade, IND# 58,443 ) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)
  • Category: Oncology
    IRB Code: 100878
    Study Title: AALL08B1, Classification of Newly Diagnosed Acute lymphoblastic Leukemia (ALL)
  • Category: Oncology
    IRB Code: 100880
    Study Title: AALL0932, Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)
  • Category: Oncology
    IRB Code: 120326
    Study Title: AALL1131, A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum
  • Category: Oncology
    IRB Code: 90995
    Study Title: AAML0631 Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide (Trisenox, IND#103,331) during Consolidation
  • Category: Oncology
    IRB Code: 90651
    Study Title: AAML08B1; Biology Study of Transient Myeloproliferative Disorder (TMD) in Children with Down Syndrome (DS)
  • Category: Oncology
    IRB Code: 110771
    Study Title: AAML1031, A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND#69896, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD
  • Category: Oncology
    IRB Code: 611105
    Study Title: ABTR01B1, A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors
  • Category: Oncology
    IRB Code: 110554T
    Study Title: ACCL0933 A Randomized Open-Label Trial of Caspofungin versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)
  • Category: Oncology
    IRB Code: 70436
    Study Title: ACNS0332: Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
  • Category: Oncology
    IRB Code: 90215
    Study Title: ACNS0333, Treatment of Atypical Teratoid/Rhabdoid Tumors of the Central Nervous System with Surgery, Intensive Chemotherapy, and 3-D Conformal Radiation
  • Category: Oncology
    IRB Code: 70861
    Study Title: ACNS0334: A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children < 36 Months Old with Intensive Induction Chemotherapy with Methotrexate Followed by Consolidation with Stem Cell Rescue vs. the Same Therapy Without Methotrexate (ACNS0334)
  • Category: Oncology
    IRB Code: 1012123
    Study Title: ACNS0821 Temozolomide with Irinotecan versus Temozolomide, Irinotecan plus Bevacizumab (NSC# 704865, BB-IND# 7921) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized Phase II Screening Trial
  • Category: Oncology
    IRB Code: 1011118
    Study Title: ACNS0822 A Randomized Phase II/III Study of Vorinostat (IND# 71976) and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab (IND # 7921) and Temozolomide in Newly Diagnosed High Grade Glioma
  • Category: Oncology
    IRB Code: 100544
    Study Title: ACNS0831 Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years
  • Category: Oncology
    IRB Code: 100985T
    Study Title: ACNS0927 A Phase 1/2 Study of Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat) and Local Irradiation, Followed by Maintenance SAHA in Children with Newly Diagnosed Diffuse Intrinsic Pontine Gliomas (DIPG)
  • Category: Oncology
    IRB Code: 120439
    Study Title: ACNS1021, A Phase II Study of Sunitinib (NSC# 736511, IND# 74019) in Recurrent, Refractory or Progressive High Grade Glioma and Ependymoma Tumors in Pediatric and Young Adult Patients
  • Category: Oncology
    IRB Code: 120659
    Study Title: ACNS1022, A Phase II Randomized Trial of Lenalidomide (NSC # 703813, IND # 70116) in Pediatric Patients with Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
  • Category: Oncology
    IRB Code: 120660
    Study Title: ACNS1123 Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT)
  • Category: Oncology
    IRB Code: 100329
    Study Title: Addition of Ginger to Control Difficult Chemotherapy-Induced Nausea and/or Vomiting in Adolescents - A Questionnaire
  • Category: Oncology
    IRB Code: 100104
    Study Title: Adolescents and Young Adults with Cancer and their Parents: The Influence of Dyadic Interactions on Adjustment
  • Category: Oncology
    IRB Code: 90659
    Study Title: ADVL0816 A PHASE I STUDY OF OBATOCLAX (PAN ANTI-APOPTOTIC BCL-2 FAMILY SMALL MOLECULE INHIBITOR), IN COMBINATION WITH VINCRISTINE/DOXORUBICIN/DEXRAZOXANE, IN CHILDREN WITH RELAPSED/REFRACTORY SOLID TUMORS OR LEUKEMIA
  • Category: Oncology
    IRB Code: 100218
    Study Title: ADVL0911 A PHASE 1 DOSE ESCALATION STUDY OF SENECA VALLEY VIRUS (NTX-010), A REPLICATION-COMPETENT PICORNAVIRUS, IN RELAPSED/REFRACTORY PEDIATRIC PATIENTS WITH NEUROBLASTOMA, RHABDOMYOSARCOMA, OR RARE TUMORS WITH NEUROENDOCRINE FEATURES
  • Category: Oncology
    IRB Code: 90997
    Study Title: ADVL0912, A Phase 1/2 Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Met, in Children with Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma
  • Category: Oncology
    IRB Code: 100657
    Study Title: ADVL0918, A Phase 1 Study of Temsirolimus in Combination with Irinotecan and Temozolomide in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors
  • Category: Oncology
    IRB Code: 110227
    Study Title: ADVL0921 A Phase II Study of MLN8237 (IND# 102984), a Selective Aurora A Kinase Inhibitor in Children with Recurrent/Refractory Solid Tumors and Leukemias
  • Category: Oncology
    IRB Code: 100991
    Study Title: ADVL1011 A PHASE 1 STUDY OF JAK INHIBITION (INCB018424) IN CHILDREN WITH RELAPSED OR REFRACTORY SOLID TUMORS, LEUKEMIAS, AND MYELOPROLIFERATIVE NEOPLASMS
  • Category: Oncology
    IRB Code: 1012128
    Study Title: ADVL1014, A Phase I dose escalation study of REOLYSIN, a replication competent reovirus, in pediatric patients with relapsed or refractory solid tumors
  • Category: Oncology
    IRB Code: 110553
    Study Title: ADVL1112 A PHASE 1 STUDY OF IMETELSTAT, A TELOMERASE INHIBITOR, IN CHILDREN WITH REFRACTORY OR RECURRENT SOLID TUMORS AND LYMPHOMAS
  • Category: Oncology
    IRB Code: 110984
    Study Title: ADVL1114, A Phase 1 Study of Temsirolimus (CCI-779, IND#61010) in Combination with Intensive Re-induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma
  • Category: Oncology
    IRB Code: 120330
    Study Title: ADVL1115, A Phase 1 Study of AMG 386 (IND# 114215), an Angiopoietin Neutralizing Peptibody, in Children with Relapsed or Refractory Solid Tumors, including CNS Tumors
  • Category: Oncology
    IRB Code: 120120
    Study Title: ADVL1121, A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (IND# 69896) in Children and Young Adults with Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
  • Category: Oncology
    IRB Code: 120664
    Study Title: ADVL1221 A Phase II Study of Cixutumumab (IMC-A12; IND# 100947) in Combination with Temsirolimus (IND# 61010) in Pediatric Patients with Recurrent or Refractory Solid Tumors
  • Category: Oncology
    IRB Code: 80404
    Study Title: AEWS07B1 A Children?s Oncology Group Protocol for Collecting and Banking Ewing Sarcoma Specimens (At Initial Diagnosis)
  • Category: Oncology
    IRB Code: 1012122
    Study Title: AEWS1031 A Phase III Randomized Trial of Adding Vincristine-topotecan-cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma
  • Category: Oncology
    IRB Code: 911110
    Study Title: AHEP0731 Treatment of Children with All Stages of Hepatoblastoma
  • Category: Oncology
    IRB Code: 70106
    Study Title: AHOD04B1, Hodgkin Disease (HD) Banking Study.
  • Category: Oncology
    IRB Code: 811127
    Study Title: ALTE05N1 Umbrella Long-Term Follow-up Protocol
  • Category: Oncology
    IRB Code: 90216
    Study Title: ALTE07C1, Neuropsychological, Social, Emotional and Behavioral Outcomes in Children with Cancer
  • Category: Oncology
    IRB Code: 120661
    Study Title: An Open Label, Single Arm, Multi-center Pharmacokinetic Study of Intravenous Erwinaze (asparaginase Erwinia chrysanthemi) Following Allergy to Native E. Coli Asparaginase (Elspar or Kidrolase), Pegaspargase (Oncaspar) or Calaspargase pegol (EZN-2285) in Children, Adolescents and Young Adults with Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
  • Category: Oncology
    IRB Code: 70968
    Study Title: An Open-Label Treatment Protocol for the Use of Voraxaze as Adjunctive Treatment for Patients Experiencing or at Risk of Methotrexate Toxicity.
  • Category: Oncology
    IRB Code: 120544
    Study Title: An open-label, cross-over, pharmacokinetic study to assess the safety and pharmacokinetics of transdermal granisetron (Sancuso patch) and IV granisetron in a pediatric oncology population (aged 13 to 17 years).
  • Category: Oncology
    IRB Code: 80403
    Study Title: AOST06B1 A Children?s Oncology Group Protocol for Collecting and Banking Osteosarcoma Specimens
  • Category: Oncology
    IRB Code: 100543
    Study Title: ARAR0332 Treatment of Adrenocortical Tumors with Surgery plus Lymph Node Dissection and Multiagent Chemotherapy
  • Category: Oncology
    IRB Code: 60536
    Study Title: AREN03B2: Renal Tumors Classification, Biology, and Banking Study
  • Category: Oncology
    IRB Code: 70544
    Study Title: AREN0533 Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
  • Category: Oncology
    IRB Code: 90994
    Study Title: AREN0534 Treatment for Patients with Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor
  • Category: Oncology
    IRB Code: 80562
    Study Title: ARST0332 Risk-Based Treatment for Pediatric Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age
  • Category: Oncology
    IRB Code: 100215
    Study Title: ARST08P1: A Pilot Study to Evaluate Novel Agents (Temozolomide and Cixutumumab [IMC-A12, Anti-IGF-IR Monoclonal Antibody, IND #100947, NSC # 742460]) in Combination with Intensive Multi-Agent Interval Compressed Therapy for Patients with High-Risk Rhabdomyosarcoma
  • Category: Oncology
    IRB Code: 1010112
    Study Title: ARST0921 A Randomized Phase II Trial of Bevacizumab (IND# 7921, Avastin) and Temsirolimus (IND# 61010, Torisel) in Combination with Intravenous Vinorelbine and Cyclophosphamide in Patients with Recurrent/Refractory Rhabdomyosarcoma
  • Category: Oncology
    IRB Code: 120323
    Study Title: BMS CA180-372 (COG AALL1122) A Phase 2 Multi-Center Historically-Controlled Study of Dasatinib Added to Standard Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
  • Category: Oncology
    IRB Code: 100882
    Study Title: California Childhood Leukemia Study
  • Category: Oncology
    IRB Code: 110664
    Study Title: Childhood Cancer Survivor Study
  • Category: Oncology
    IRB Code: 80210
    Study Title: COG ASCT0431 A Randomized Trial of Sirolimus-Based Graft versus Host Disease Prophylaxis after Hematopeietic Stem Cell Transplantation in Relapsed ALL.
  • Category: Oncology
    IRB Code: 60650
    Study Title: COG: AADM0211: Eligibility Screening Tool for COG Developmental Therapeutics/Phase I Consortium Clinical Research Protocols
  • Category: Oncology
    IRB Code: 40212
    Study Title: COG: AALL0232: High Risk B-Percursor Acute Lymphoblastic Leukemia
  • Category: Oncology
    IRB Code: 61088
    Study Title: COG: AALL05B1: A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens
  • Category: Oncology
    IRB Code: 41171
    Study Title: COG: ACNS02B3: A Children's Oncology Group Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens
  • Category: Oncology
    IRB Code: 51103
    Study Title: COG: ADVL04P2: A Phase I/II Pilot Study of Chemoimmunotherapy with Epratuzamab for Children with Refractory CD22-Positive Acute Lymphoblastic Leukemia
  • Category: Oncology
    IRB Code: 01-020
    Study Title: COG: ANBL0032: Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloblative Therapy and Autologous Stem Cell Rescue
  • Category: Oncology
    IRB Code: 01-008IHT
    Study Title: COG: ANBL00B1: Neuroblastoma Biology Study
  • Category: Oncology
    IRB Code: 70101
    Study Title: COG: AREN0321: Treatment of High Risk Renal Tumors
  • Category: Oncology
    IRB Code: 70102
    Study Title: COG: AREN0532: Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor
  • Category: Oncology
    IRB Code: 70215
    Study Title: COG: ARST0531: Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) versus VAC Alternating with Vincristine and Irinotecan (VI) for Patients with Intermediate-Risk Rhabdomyosarcoma (RMS).
  • Category: Oncology
    IRB Code: 00-017T
    Study Title: COG: D9902: A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol
  • Category: Oncology
    IRB Code: 96-009
    Study Title: COG: L4941: National Wilms Tumor Late Effects Study
  • Category: Oncology
    IRB Code: 100666
    Study Title: CPT-SIOP-2009, Intercontinental Multidisciplinary Registry and Treatment Optimization study for Patients with Choroid Plexus Tumors
  • Category: Oncology
    IRB Code: 90998
    Study Title: Defibrotide for Patients with Hepatic Veno-occlusive Disease (VOD): A Treatment IND Study (Under CFR 312.34)
  • Category: Oncology
    IRB Code: 1111100
    Study Title: Expanded Access of Prochymal (Ex-Vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD
  • Category: Oncology
    IRB Code: 080219T
    Study Title: Liposomal Muramyl Tripeptide Phosphatidyl Ethanolamine (L-MTP-PE): Compassionate Access for High Risk Osteosarcoma
  • Category: Oncology
    IRB Code: 111096
    Study Title: Mathematical Modeling of Mutant p53 in a Li-Fraumeni Syndrome Population
  • Category: Oncology
    IRB Code: 80776
    Study Title: NIH: Oncofertility Consortium: Fertility Preservation in Women and Girls with Cancer
  • Category: Oncology
    IRB Code: 111095
    Study Title: NMTRC 001: A Feasibility Trial using Molecular-Guided Therapy for the Treatment of Patients with Refractory or Recurrent Neuroblastoma
  • Category: Oncology
    IRB Code: 100324
    Study Title: Pilot Project Grant: To Study FGFR3 Expression and Mutations in Pediatric Cancers
  • Category: Oncology
    IRB Code: 120543
    Study Title: Pilot Project: Assessing the Feasibility of Applying Molecular Profiling Data to Clinical Decision Making in Childhood, Adolescent, and Young Adult Cancers
  • Category: Oncology
    IRB Code: 120555
    Study Title: Pilot Project: Gastrointestinal Microbe Population Changes in Newly Diagnosed Pediatric Pre-B Acute Lymphoblastic Leukemia Patients
  • Category: Oncology
    IRB Code: 111199
    Study Title: Pilot Project: Molecular Profiles of Refractory and Recurrent Childhood, Adolescent, and Young Adult Cancers
  • Category: Oncology
    IRB Code: 111097
    Study Title: Prospective Data Collection for Patients with Acute Lymphoblastic and Acute Myeloid Leukemia (A companion protocol to Pilot Project: Molecular Profiles of Refractory and Recurrent Childhood, Adolescent, and Young Adult Cancers)
  • Category: Oncology
    IRB Code: 80209
    Study Title: Protocol for the Enrollment on the Official COG Registry, the Childhood Cancer Research Network (CCRN)
  • Category: Oncology
    IRB Code: 02-022IH
    Study Title: The National Marrow Donor Program? and Center for International Blood and Marrow Transplant Research (CIBMTR) Protocol for a Research Sample Repository for Allogeneic Hematopoietic Stem Cell Transplantation
  • Category: Oncology
    IRB Code: 02-023IH
    Study Title: The National Marrow Donor Program? and Center for International Blood and Marrow Transplant Research (CIBMTR): A Research Database for Hematopoietic Stem Cell Transplantation
  • Category: Oncology
    IRB Code: 1010108
    Study Title: Therapeutic Potential of TOR Pathway Inhibitors in Pediatric ALL
  • Category: Oncology
    IRB Code: 90996
    Study Title: Yondelis? (trabectedin) Single Patient Compassionate Use / Expanded Access in Soft Tissue Sarcoma
HYUNDAI CANCER INSTITUTE
WHAT TO EXPECT
CLINICAL TRIALS
ONCOLOGY FLOOR TOUR
SUPPORT SERVICES
MAKE AN APPOINTMENT
RELATED HEALTH TOPICS:
ONCOLOGY
HEALTH TOPICS A-Z
CENTERS:
RESEARCH INSTITUTE
HYUNDAI CANCER INSTITUTE
RELATED SERVICES:
HEM/ONC FELLOWSHIP
RELATED SPECIALTIES:
HEMATOLOGY
ONCOLOGY
RELATED LINKS:
FIND SPECIALISTS
ARTICLES
STORIES
NEWS
VIDEO

For more information about The CHOC Children's Institutes,
please email us at institutes@choc.org or call
(800) 329-2900.


spacer

Facebook  Twitter  Pinterest  Instagram  Foursquare  LinkedIn  YouTube  RSS  CHOC Blog

US News     CAPE Award   Magnet      Beacon Award      Most Trusted Brand     Leapfrog

chocChildren's Hospital of Orange County | UCI University of California, Irvine

Children's Hospital of Orange County is affiliated with UC Irvine Healthcare and UC Irvine School of Medicine

CHOC Children's - 1201 W La Veta Ave, Orange, CA. Phone: 714-997-3000. .